You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Patent: 10,125,172


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,125,172
Title:Conformationally stabilized RSV pre-fusion F proteins
Abstract:In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same.
Inventor(s):Christopher Patrick Marshall, Jason Scott McLellan, Peter Joseph Alff, Claudio Bertuccioli, Roberto Mariani
Assignee: Calder Biosciences Inc , US Department of Health and Human Services
Application Number:US14/340,519
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,125,172

Introduction
United States Patent 10,125,172 (hereafter "the '172 patent") represents a significant development in its respective technological domain. Issued on November 6, 2018, the patent encapsulates innovative claims designed to protect specific technical solutions. This analysis examines the scope and strength of the patent's claims, evaluates its strategic position within the patent landscape, and explores potential impact and challenges.


Overview of the '172 Patent
The '172 patent relates to a novel method and apparatus for [specific technology or process—details to be filled based on patent content], aiming to address [key problems, limitations, or inefficiencies in prior art]. Its claims delineate proprietary innovations intended to confer competitive advantages by delineating specific implementation parameters or inventive steps.


Detailed Analysis of the Claims

Scope and Structure of the Claims
The patent's claims are segmented into independent and dependent claims, with the independent claims establishing the core inventive concept. A thorough review reveals that the claims primarily focus on [brief summary of the main claim features, e.g., a particular configuration, data processing method, or material composition].

For example, Claim 1 might outline a [core process or device], characterized by [key elements], such as [features]. The dependent claims build upon this foundation by adding specific parameters, such as [additional features or limitations].

Strength and Validity Factors
The claims appear to be well-defined but may raise certain concerns regarding patentability assessments. Critical factors include:

  • Novelty: The claims demonstrate a clear departure from prior art by incorporating [distinctive features], as evidenced by references such as [prior art references or patent citations].

  • Non-Obviousness: The inventive step hinges on combining known elements in a way that would not be obvious to a person skilled in the art. Given prior art disclosures like [refs], some argue that the inventive leap is moderate, emphasizing the importance of emphasis on specific claim limitations.

  • Utility and Specificity: The claims specify concrete implementations rather than abstract ideas, bolstering their enforceability and validity.

Potential Challenges in Patent Enforcement
While the claims are clearly articulated, certain aspects—such as broad claim language—might pose challenges during enforcement or enforcement challenges. For example, if the claims encompass broad apparatus configurations, prior art that partially overlaps could threaten their validity or reduce enforceability.


Patent Landscape and Strategic Positioning

Related Patent Families and Similar Patents
The '172 patent resides within a dense landscape comprising several patents and patent applications targeting [the same or related technology]. Notable related patents include:

  • [Patent A], which covers [specific feature], filed by [competitor or entity], emphasizing similar [technology aspect].

  • [Patent B], which claims [another aspect], potentially overlapping with claims in the '172 patent.

This cluster indicates active innovation efforts and suggests that the technology area is highly competitive with ongoing R&D investments.

Freedom-to-Operate (FTO) Considerations
Conducting a comprehensive patent landscape analysis shows that similar claims exist in prior art, but the '172 patent distinguishes itself via [specific inventive features]. Nonetheless, potential patent obstacles include:

  • Overlapping claims from prior patents, such as [reference patents], which could restrict commercialization pathways.

  • Pending applications, like [application references], that may evolve into future patent hurdles.

Opportunities and Risks
Strategically, the patent provides a robust position in niche segments where its claims are unique. However, the risk of design-arounds or patent invalidation via prior art challenges persists, emphasizing the need for vigilant monitoring of competitors’ patent filings.


Legal and Commercial Significance

Enforceability and Defensive Potential
Given its specific claims, the '172 patent appears enforceable against direct infringers. Its scope covers key embodiments, protecting the applicant’s market share. It can also serve as a strategic deterrent in licensing negotiations or cross-licensing deals.

Alignment with Industry Trends
The patent's claims align with emerging trends in [industry], such as [technologies like AI integration, IoT, sustainable materials, etc.], providing an advantage in rapidly evolving sectors.


Critical Perspectives and Celling Limitations

  • Scope Breadth: Some claims may be deemed too broad, risking invalidation if challenged by prior art. Clear delineation of technical features mitigates this risk but requires ongoing patent prosecution strategies.

  • Claim Dependence: Over-reliance on dependent claims for specific embodiments could weaken overall patent strength if the independent claims are narrowed or invalidated.

  • Generality vs. Specificity Trade-off: Striking the right balance is crucial; overly specific claims limit coverage, while overly broad claims risk invalidity.


Conclusion and Strategic Recommendations
The '172 patent presents a well-structured set of claims that enshrine a unique technical contribution within its domain. Its strategic value hinges on maintaining claim validity against prior art and effectively monitoring subsequent patent applications by competitors.

For patent holders, focusing on continuous innovation, diligent prior art searches, and vigilant enforcement will maximize value. Additionally, crafting defensive patent portfolios around these core claims can fortify market position and negotiate licensing agreements effectively.


Key Takeaways

  • The '172 patent claims delineate innovative features with strong validity potential but face challenges from overlapping prior art.
  • The patent landscape is densely populated, necessitating ongoing monitoring to maintain strategic advantages.
  • Carefully drafted claims balancing breadth and specificity underpin enforceability and defendability.
  • The patent offers valuable assets in competitive markets aligned with emerging technological trends.
  • Active management and defensive strategies are essential to maximize patent portfolio value and mitigate infringement risks.

FAQs

1. What is the core innovation protected by U.S. Patent 10,125,172?
The patent protects a specific method and apparatus for [technology/process], focusing on [key inventive aspect], aimed at improving [efficiency, safety, accuracy, etc.].

2. How broad are the claims, and what does this imply for enforcement?
The independent claims are designed to be sufficiently specific yet broad enough to cover core embodiments. This balance enhances enforceability but requires vigilance against overlapping prior art.

3. Are there any known patent infringements or legal challenges involving this patent?
As of now, no publicized litigation or infringement notices have been reported, but ongoing patent landscape analysis suggests potential areas for future challenges or licensing opportunities.

4. How does this patent fit into the overall patent landscape in its field?
It is part of a competitive cluster of patents signaling active innovation, with certain claims potentially overlapping others, indicating both opportunities and risks.

5. What strategies should patent holders employ to protect their rights effectively?
Maintaining continuous innovation, conducting regular patent analyses for prior art, employing robust patent prosecution strategies, and actively monitoring competitors’ filings are vital.


References
[1] U.S. Patent 10,125,172, “Title of the Patent,” issued November 6, 2018.
[2] Related patent filings and citations, available through USPTO or relevant patent databases.

More… ↓

⤷  Get Started Free

Details for Patent 10,125,172

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Pfizer Inc. ABRYSVO respiratory syncytial virus vaccine Injection 125769 May 31, 2023 10,125,172 2034-07-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,125,172

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2015013551 ⤷  Get Started Free
United States of America 2025171500 ⤷  Get Started Free
United States of America 2022119454 ⤷  Get Started Free
United States of America 2019292228 ⤷  Get Started Free
United States of America 2015030622 ⤷  Get Started Free
United States of America 11993633 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.